U.S. Gastric Cancer Diagnostics Market Summary

The U.S. gastric cancer diagnostics market size was valued at USD 489.09 million in 2024 and is projected to reach USD 897.20 million by 2033, expanding at a CAGR of 7.08% from 2025 to 2033. Market growth is being driven by continuous advancements in diagnostic technologies, rising awareness among patients and healthcare providers, and the expansion of healthcare infrastructure across the country. According to the American Cancer Society (ACS), gastric cancer accounted for 26,890 new cases and 10,880 deaths in 2024, with an estimated 30,300 new cases and 10,780 deaths expected in 2025, highlighting the growing healthcare burden.

Innovative technologies such as liquid biopsies, next-generation sequencing (NGS), and AI-driven imaging are transforming the landscape of gastric cancer diagnostics. These methods support early detection, accurate staging, and a deeper understanding of tumor biology, ultimately enabling the development of more personalized treatment strategies. Additionally, advanced endoscopy procedures such as narrow-band imaging and confocal laser endomicroscopy improve diagnostic accuracy and patient care outcomes. The integration of molecular diagnostics further facilitates precision medicine by enabling targeted therapies tailored to genetic variations. As the demand for non-invasive, accurate, and efficient solutions grows, the adoption of these advanced technologies continues to accelerate.

Key Market Trends & Insights

• Reagents and consumables dominated the market with a revenue share of 60.88% in 2024 and are projected to grow at the fastest pace during the forecast period. Their essential role in diagnostic methods, including histopathology, immunohistochemistry, and molecular testing, ensures consistent demand, making them a vital segment in clinical laboratories and hospital-based diagnostic facilities.
• Adenocarcinoma remained the leading segment, holding a revenue share of 85.64% in 2024, and is expected to experience the fastest CAGR over the coming years. This dominance is largely due to adenocarcinoma representing the majority of gastric cancer cases worldwide. According to an American Cancer Society (ACS) article published in April 2024, adenocarcinoma accounts for two-thirds of esophageal cancer cases in high-HDI countries, strongly associated with risk factors such as obesity, gastroesophageal reflux disease (GERD), and Barrett’s esophagus.
• Hospitals accounted for the largest share of 64.96% in the U.S. gastric cancer diagnostics market in 2024. Growth within this segment is driven by the adoption of cutting-edge diagnostic tools, particularly those leveraging artificial intelligence (AI) and machine learning (ML). These technologies enable greater precision, reduce diagnostic errors, and help healthcare professionals provide faster and more accurate results, ultimately improving patient care and outcomes.
• The U.S. continues to play a key role in the global gastric cancer diagnostics market, supported by strong healthcare infrastructure, high healthcare expenditure, and the increasing adoption of advanced technologies for early detection. Although the overall incidence of gastric cancer is lower in the U.S. compared to regions like East Asia, the rising focus on early diagnosis and patient awareness campaigns is fostering consistent market growth.

Order a free sample PDF of the U.S. Gastric Cancer Diagnostics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 489.09 million
• 2033 Projected Market Size: USD 897.20 million
• CAGR (2025 - 2033): 7.08%

Key Companies & Market Share Insights

Key players in the U.S. gastric cancer diagnostics market include Natera, Inc., Illumina, GE Healthcare, QIAGEN, and Thermo Fisher Scientific. The adoption of cutting-edge technologies such as artificial intelligence, next-generation sequencing, and liquid biopsy is greatly enhancing the accuracy and efficiency of cancer diagnostics. These innovations reflect the market’s ongoing evolution, with both major companies and emerging technologies contributing to its dynamic growth and advancement.

Key Players

• Illumina, Inc
• Guardant Health
• Natera, Inc
• Thermo Fisher Scientific
• QIAGEN
• Freenome Holdings Inc.
• Exact Sciences Corporation
• PathAI, Inc
• GE Healthcare

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. gastric cancer diagnostics market is poised for sustained growth, driven by innovations in diagnostic technologies, increasing awareness, and strong healthcare infrastructure. The dominance of reagents and consumables highlights the essential role of these products in diagnostic procedures, while the prevalence of adenocarcinoma continues to shape demand for precise testing methods. Hospitals remain central to this market due to their rapid adoption of AI and advanced imaging tools. With rising investments in research and a growing emphasis on early detection, the U.S. market is expected to remain a leader in advancing diagnostic capabilities and improving patient outcomes.